OLMA - Olema Pharma shares early-stage data for cancer therapy for women

Olema Pharmaceuticals (NASDAQ:OLMA)announced that three patients experienced a reduction in the tumor size (partial responses) out of 24 efficacy-evaluable patients in its ongoing Phase 1/2 clinical trial for OP-1250 against metastatic breast cancer and other women’s cancers. As of Nov. 01, 41 patients who were heavily pretreated were part of the study across 7 dose cohorts. Out of three partial responses, two were confirmed partial responses, and one was an unconfirmed partial response with a target lesion reduction of 100%. However, in the unconfirmed response, the patient has experienced a new lesion at a follow-up visit. Across all cohorts, the overall response rate (ORR) was 8% (2/24), and the clinical benefit rate (CBR) was 29% (7/24). And at the recommended Phase 2 dose (RP2D) range of once-daily 60-120 mg OP-1250, ORR and CBR stood at 17% and 46%, respectively. On the safety front, a maximum tolerated dose was not found,

For further details see:

Olema Pharma shares early-stage data for cancer therapy for women